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Ovalbumin loaded chitosan and pectin based composite nanoparticles were obtained. The mean size, 
morphology and zeta potential of the nanoparticles were determined by dynamic light scattering (DLS) and 
atomic force microscopy (AFM). Effect oral administration of obtained nanoparticles on the immune re-
sponse was studied.  
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1. INTRODUCTION 
 
Polysaccharides are widespread biopolymers, which 
can be used as drug delivery systems [1]. Recently, a lot 
of attention is given to chitosan, pectin and their deriv-
atives through their high biocompatibility, biodegrada-
bility, low toxicity and high affinity to macromolecules 
and cells. Currently, oral delivery is still the preferred 
and common route of drug administration. However, 
the main disadvantages of this method are instability 
of drugs under the action of different environmental 
conditions, such as low pH in the stomach, protease 
affection in small intestine, and microflora digestion in 
colon, particularly relates to drugs based on bioactive 
substances, peptides, proteins, nucleic acids, as well as 
their limited absorption in the intestine due weak ad-
hesion. Solution of the problem of this route of admin-
istration is the creation of new drug delivery systems. 
Composite, nano-sized drug delivery systems are able 
to overcome a variety of biological barriers in the or-
ganism (intestine - blood channel, blood channel - tis-
sue, blood-brain barrier), reduce the side effects (toxici-
ty and allergenicity), prolong of a drug action in the 
organism [2]. In this study, foundation of creation of 
composite particles for oral administration is the com-
plexation between oppositely charged polysaccharides 
and proteins. 
 
2. MATERIALS AND METHODS 
 
2.1 Materials 
 
For nanoparticles preparation crab shell chitosan 
with molecular weight 200 kDa and deacetylation de-
gree 86% (ZAO “Bioprogress”, Moscow region, Russia), 
lowmethoxyl willow herb pectin with 14 degree of 
esterification (Vyatka State University, Kirov region, 
Russia) and ovalbumin (AppliChem, Germany) were 
used. 
 
2.2 Preparation of Nanoparticles 
 
Chitosan was dissolved in 0.25 acetic acid solution. 
The pH of chitosan solutions was initially adjusted with 
0.25 NaOH to 5.2. Pectin and ovalbumin solutions 
were prepared in deionized water. Chitosan/Ovalbumin-
nanoparticles (Chi/OVA-NPs) were obtained in a one-
step procedure based on the ionotropic gelation with 
sodium tripolyphosphate (TPP) with following cover 
nanoparticles with pectin and 0.5 mM CaCl2.  
PEG-2000 was added to 0.4 solution of N-acetyl-
chitosan to final concentration of 5 mg/ml. After that 
0.1 ovalbumin solution was added to N-acetyl-chitosan 
solution at vigorous stirring at 30 rpm. Then 0.1 TPP 
(pH 7.0) was added to this solution. The formed disper-
sion was additionally stirred at 30 rpm during 20 min at 
22С. Chi/OVA-NPs were separated by centrifugation 
(14000 g, 20 min) and then resuspended in deionized 
water. 
Nanoparticles (3.2 mg/ml) was injected under gentle 
stirring into a beaker containing pectin solution 
(1.25 mg/ml) and stirred for 30 min. After that, Chi-
tosan/Ovalbumin/Pectin-nanoparticles (Chi/OVA/Pec-
NPs) were separated by centrifugation (14000 g, 20 min) 
and then resuspended in 0.5 ml CaCl2. Then 
Chi/OVA/Pec-NPs were separated by centrifugation 
(14000 g, 10 min) and freeze-dried. 
 
2.3 Size and Zeta Potential Measurements 
 
The mean particle size was measured by AFM using 
NTEGRA Prima microscope (NT-MDT, Russia) in a 
semi-contact mode with cantilevers NSG01 and zeta 
potential were determined by DLS using 90 Plus 
Particle Size Analyzer (Brookhaven instruments 
corporation, USA) at a scattering angle 900 and 661 nm 
wavelength. 
 
2.4 Loading Efficiency 
 
The loading efficiency (LE) value was calculated ac-
cording to the following equation:  
 
 LE  [(W0–W)/W0]∙100,  
 
where W0 is the total amount of OVA used to pre-
pare nanoparticles, W is the amount present in the su-
pernatant after centrifugation at 14000 rpm for 20 min. 
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Samples were analyzed for OVA content using Brad-
ford method. 
 
2.5 In Vitro Release Studies 
 
The release of OVA from Chi/OVA/Pec-NPs were 
carried out in model gastric and intestinal juices which 
were prepared according to procedure described in the 
article [3]. The Chi/OVA/Pec-NPs were incubated in a 
solution model gastric juice for 2 hours, after that 
Chi/OVA/Pec-NPs were separated by centrifugation 
(14000 g, 20 min) and then nanoparticles were resus-
pended in model gastric juice and were incubated dur-
ing the 24 hours (t  37C). Samples were analyzed for 
OVA content using Bradford method. 
 
2.6 Oral Immunization 
 
Immunization was carried out according to the pro-
cedure described in the article [4]. Antibody titers to 
OVA were assessed using an enzyme-linked immuno-
sorbent assay (ELISA). 
 
2.7 Statistical Analysis 
 
Results are presented as mean ± standard deviation 
(SD). The significance of differences between means 
was evaluated using Mann-Whitney test. 
 
3. RESULTS AND DISCUSSION 
 
Composite particles were formed by ionotropic gela-
tion method. At first complex between oppositely 
charged chitosan and ovalbumin was obtained, then 
complex was cross-linked with TPP. The yield of parti-
cles ranged from 14 to 16. Maximum loading efficiency 
of OVA (60) was obtained at a ratio OVA:Chi equal 
1:3.6 (Table 1).  
 
Table 1 – Influence of the ratio of ovalbumin and chitosan on the loading efficiency of protein  
 
№ 
 
Ratio of ovalbumin 
and chitosan 
Concentration, mg/ml Loading efficiency,  
 Chi OVA TPP 
1 
1:5,3 2,10 0,40 0,08 23 
2 
1:4,0 1,42 0,35 0,12 49 
3 
1:3,8 1,60 0,42 0,09 48 
4 
1:3,6 1,80 0,50 0,10 60 
5 
1:3,2 1,80 0,55 0,14 46 
 
Further, this ratio of polymers was used for the 
preparation of the particles. The Chi/OVA-NPs were 
coated by pectin and treated with CaCl2 solution for ad-
ditional crosslinking. Amount of pectin was selected em-
pirically (Fig. 1) to obtain a stable, nano-sized particles. 
The graph shows that the pectin concentration of 
1.25 mg/ml is sufficient for the formation of stable parti-
cles.  
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Fig. 1 – The influence of the pectin concentration on zeta potential of composite particles 
 
According to the data AFM (Fig. 2) and the DLS par-
ticles are not covered by pectin have a size of 50  10 nm 
and zeta potential of 19  4.6 mV. After covering the pec-
tin particle size slightly increased to 60  10 nm, and the 
zeta potential was equal to -44  1.5 mV. 
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Fig. 2 – Morphology and particle size measured by AFM of Chi/OVA-NPs (a), Chi/OVA/Pec-NPs (b) 
 
Investigation of the stability of the composite parti-
cles in model gastric and intestinal juices (in vitro) 
showed that ovalbumin completely released from the 
particles in the gastric environment in 2 hours. 
The effect of the composite nanoparticles on the im-
mune response was studied. In the experiment, female 
A/HeJ mice (20 – 25 g) were immunized three times with 
the antigen administered orally. Repeated oral immun-
izations were carried out on day 7 and 14 after the pri-
mary immunization. On day 21 blood samples were tak-
en from animals. Fig. 3 shows ELISA results. Found 
that the composite particles reduced immune response 
comparing to control and have an immunosuppressive 
action.
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Fig. 3 – Effect of OVA loaded composite nanoparticles on immunoglobulin G (IgG) production. Data are presented as mean ± SD 
(n  9). *P  0.05 comparing to control  
 
4. CONCLUSIONS 
 
Thus, developed a method for producing chitosan 
and pectin based ovalbumin loaded composite nanopar-
ticles release the protein in the gastric environment 
and possess immunosuppressive action. In further 
studies is planned to create nanoparticles having im-
munoenhancing action by using pectin, which has abil-
ity to be resistant to proteases and amylases, which are 
active in the gastrointestinal tract. 
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